Your browser doesn't support javascript.
loading
Cognitive Trajectories in Preclinical and Prodromal Alzheimer's Disease Related to Amyloid Status and Brain Atrophy: A Bayesian Approach.
Teipel, Stefan J; Dyrba, Martin; Levin, Fedor; Altenstein, Slawek; Berger, Moritz; Beyle, Aline; Brosseron, Frederic; Buerger, Katharina; Burow, Lena; Dobisch, Laura; Ewers, Michael; Fliessbach, Klaus; Frommann, Ingo; Glanz, Wenzel; Goerss, Doreen; Gref, Daria; Hansen, Niels; Heneka, Michael T; Incesoy, Enise I; Janowitz, Daniel; Keles, Deniz; Kilimann, Ingo; Laske, Christoph; Lohse, Andrea; Munk, Matthias H; Perneczky, Robert; Peters, Oliver; Preis, Lukas; Priller, Josef; Rostamzadeh, Ayda; Roy, Nina; Schmid, Matthias; Schneider, Anja; Spottke, Annika; Spruth, Eike Jakob; Wiltfang, Jens; Düzel, Emrah; Jessen, Frank; Kleineidam, Luca; Wagner, Michael.
Affiliation
  • Teipel SJ; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Dyrba M; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
  • Levin F; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Altenstein S; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Berger M; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Beyle A; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.
  • Brosseron F; Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
  • Buerger K; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
  • Burow L; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
  • Dobisch L; German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.
  • Ewers M; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Fliessbach K; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Frommann I; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Glanz W; German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.
  • Goerss D; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Gref D; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
  • Hansen N; University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany.
  • Heneka MT; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
  • Incesoy EI; University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany.
  • Janowitz D; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Keles D; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Kilimann I; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
  • Laske C; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Lohse A; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
  • Munk MH; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg.
  • Perneczky R; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
  • Peters O; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany.
  • Preis L; Department for Psychiatry and Psychotherapy, University Clinic Magdeburg, Magdeburg, Germany pGerman Center for Neurodegenerative Diseases (DZNE), T¨ubingen, Germany.
  • Priller J; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Rostamzadeh A; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Roy N; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
  • Schmid M; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany.
  • Schneider A; German Center for Neurodegenerative Diseases (DZNE), T¨ubingen, Germany.
  • Spottke A; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of T¨ubingen, T¨ubingen, Germany.
  • Spruth EJ; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany.
  • Wiltfang J; German Center for Neurodegenerative Diseases (DZNE), T¨ubingen, Germany.
  • Düzel E; Department of Psychiatry and Psychotherapy, University of T¨ubingen, T¨ubingen, Germany.
  • Jessen F; German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany.
  • Kleineidam L; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Wagner M; Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany.
J Alzheimers Dis Rep ; 7(1): 1055-1076, 2023.
Article in En | MEDLINE | ID: mdl-37849637
ABSTRACT

Background:

Cognitive decline is a key outcome of clinical studies in Alzheimer's disease (AD).

Objective:

To determine effects of global amyloid load as well as hippocampus and basal forebrain volumes on longitudinal rates and practice effects from repeated testing of domain specific cognitive change in the AD spectrum, considering non-linear effects and heterogeneity across cohorts.

Methods:

We included 1,514 cases from three cohorts, ADNI, AIBL, and DELCODE, spanning the range from cognitively normal people to people with subjective cognitive decline and mild cognitive impairment (MCI). We used generalized Bayesian mixed effects analysis of linear and polynomial models of amyloid and volume effects in time. Robustness of effects across cohorts was determined using Bayesian random effects meta-analysis.

Results:

We found a consistent effect of amyloid and hippocampus volume, but not of basal forebrain volume, on rates of memory change across the three cohorts in the meta-analysis. Effects for amyloid and volumetric markers on executive function were more heterogeneous. We found practice effects in memory and executive performance in amyloid negative cognitively normal controls and MCI cases, but only to a smaller degree in amyloid positive controls and not at all in amyloid positive MCI cases.

Conclusions:

We found heterogeneity between cohorts, particularly in effects on executive functions. Initial increases in cognitive performance in amyloid negative, but not in amyloid positive MCI cases and controls may reflect practice effects from repeated testing that are lost with higher levels of cerebral amyloid.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Alzheimers Dis Rep Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Alzheimers Dis Rep Year: 2023 Document type: Article Affiliation country:
...